Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.
Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dréno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont AM, Marchand M. Kruit WH, et al. Among authors: van ojik hh. Int J Cancer. 2005 Nov 20;117(4):596-604. doi: 10.1002/ijc.21264. Int J Cancer. 2005. PMID: 15945101 Free article. Clinical Trial.
IL-12: a promising adjuvant for cancer vaccination.
Portielje JE, Gratama JW, van Ojik HH, Stoter G, Kruit WH. Portielje JE, et al. Among authors: van ojik hh. Cancer Immunol Immunother. 2003 Mar;52(3):133-44. doi: 10.1007/s00262-002-0356-5. Epub 2003 Feb 12. Cancer Immunol Immunother. 2003. PMID: 12649742 Free PMC article. Review.
Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer.
van Ojik HH, Repp R, Groenewegen G, Valerius T, van de Winkel JG. van Ojik HH, et al. Among authors: van de winkel jg. Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):207-9. doi: 10.1007/s002620050434. Cancer Immunol Immunother. 1997. PMID: 9435875 Free PMC article. Clinical Trial. No abstract available.
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.
Repp R, van Ojik HH, Valerius T, Groenewegen G, Wieland G, Oetzel C, Stockmeyer B, Becker W, Eisenhut M, Steininger H, Deo YM, Blijham GH, Kalden JR, van de Winkel JG, Gramatzki M. Repp R, et al. Among authors: van ojik hh. Br J Cancer. 2003 Dec 15;89(12):2234-43. doi: 10.1038/sj.bjc.6601367. Br J Cancer. 2003. PMID: 14676800 Free PMC article. Clinical Trial.
Immunotherapeutic perspective for bispecific antibodies.
van Spriel AB, van Ojik HH, van De Winkel JG. van Spriel AB, et al. Among authors: van ojik hh, van de winkel jg. Immunol Today. 2000 Aug;21(8):391-7. doi: 10.1016/s0167-5699(00)01659-5. Immunol Today. 2000. PMID: 10916142 Review.
16 results